Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
46 Total results for product and free and sample content found
Generics Bulletin
By Aidan Fry 27 Nov 2020
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Topic Biosimilars Deals
Scrip
08 Apr 2020
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.
Topic Coronavirus
Scrip
By Andy Smith 30 Jan 2020
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Topic Business Strategies Coronavirus Sales Earnings Vaccines
Datamonitor Healthcare
By Zara Fulton 07 Oct 2017
Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.
Topic BioPharmaceutical
Datamonitor Healthcare
By Zara Fulton 07 Oct 2017
Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.
Topic Company Analysis
Datamonitor Healthcare
By Oliver Spray 07 Oct 2017
Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.
Topic Company Analysis
Datamonitor Healthcare
By Edward Thomason 07 Oct 2017
Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier
Topic Cancer
Datamonitor Healthcare
02 Apr 2017
Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).
Topic FDA Multiple Sclerosis
Datamonitor Healthcare
29 Mar 2017
PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.
Topic Comment Wire
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
